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Abstract: The Streptococcus pyogenes Cas9 protein (SpCas9), a component of CRISPR-based immune
system in microbes, has become commonly utilized for genome editing. This nuclease forms a
ribonucleoprotein (RNP) complex with guide RNA (gRNA) which induces Cas9 structural changes
and triggers its cleavage activity. Here, electronic circular dichroism (ECD) spectroscopy was used to
confirm the RNP formation and to determine its individual components. The ECD spectra had char-
acteristic features differentiating Cas9 and gRNA, the former showed a negative/positive profile with
maxima located at 221, 209 and 196 nm, while the latter revealed positive/negative/positive/negative
pattern with bands observed at 266, 242, 222 and 209 nm, respectively. For the first time, the ex-
perimental ECD spectrum of the gRNA:Cas9 RNP complex is presented. It exhibits a bisignate
positive/negative ECD couplet with maxima at 273 and 235 nm, and it differs significantly from
individual spectrum of each RNP components. Additionally, the Cas9 protein and RNP complex
retained biological activity after ECD measurements and they were able to bind and cleave DNA
in vitro. Hence, we conclude that ECD spectroscopy can be considered as a quick and non-destructive
method of monitoring conformational changes of the Cas9 protein as a result of Cas9 and gRNA
interaction, and identification of the gRNA:Cas9 RNP complex.
Keywords: CRISPR/Cas9; DNA cleavage; ECD; spectroscopy; guide RNA; RNP complex; SpCas9
1. Introduction
In 2020, the Royal Swedish Academy of Sciences has awarded the Nobel Prize in Chem-
istry for the development of a method for genome editing, as the consequence of discovery
and research on Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and
CRISPR-associated (Cas) proteins. The CRISPR/Cas system is a fast developing technology
allowing for genome editing, i.e., for generation of small genome modifications at defined
sites of the target DNA or, in other words, for a precise, site-directed mutagenesis [1].
A wide range of potential applications and the simplicity, precision and effectiveness of
genome editing also justified the earlier announcement of CRISPR/Cas the Breakthrough of
the Year by Science journal in 2015 [2]. Despite editing approach, various Cas variants have
been used to create chimeric molecules to elucidate protein interactions, and to activate or
repress gene expression [3]. The CRISPR/Cas-based methods have been revolutionizing
biological sciences, nowadays. Clinical trials of CRISPR-mediated gene therapy have been
initiated [4]. Advanced research has been carried out for the application of CRISPR/Cas in
human disease treatments, including AIDS, hemophilia, autism spectrum disorder, and
cancer [5]. Additionally, several molecular diagnostic tools were invented for virus detec-
tion, pathogen identification, cancer mutation analysis or patient genotyping [6]. In plant
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sciences, genome-edited soybean of high nutritional value has been adopted to agriculture
recently while other crops are awaiting commercialization [7,8].
A native CRISPR/Cas system was discovered in microbes where it functions as an
adaptive immune mechanism protecting against invading viruses [9]. The majority of
prokaryotic genomes contain characteristic CRISPR locus with short (about 30 bp, on
average) repeats interspaced by unique sequences of similar size [9–11]. These spacers are
phage DNA fragments of variable sequences acquired by a microbe during past phage
infections [12]. Each spacer and repeat pair are transcribed to CRISPR RNA (crRNA),
which hybridizes with another RNA molecule, a small trans-activating crRNA (tracrRNA),
to form a guide RNA (gRNA). Hence, gRNA is composed of the tracrRNA with a stem
loop structure due to conserved nucleotide sequence and the crRNA molecule with 20 nt
variable sequence at 5′ end that can hybridize to a complementary DNA strand. Cas
protein, or usually a complex of various Cas proteins, forms a ribonucleoprotein (RNP)
complex with gRNA, which guides the protein to the target phage DNA at the location
with complementary sequence next to a short protospacer adjacent motif (PAM) of con-
served, usually 3–6 nt sequence [13,14]. Then, Cas protein destroys phage DNA by its
cleavage [15]. Further discoveries have paved the way for the utilization of this natural
defense mechanism and have led to the development of CRISPR/Cas-based systems for
DNA editing and research in eukaryotic organisms. In particular, it was found that about
100 nt long, single gRNA composed of crRNA and tracrRNA fragments linked with a
tetraloop (Figure 1) can be used instead of a native hybrid gRNA [13]. In consequence,
designing gRNA to target the desired DNA location as well as the delivery of gRNA to
target cells was simplified and single gRNA has become routinely used.
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Figure 1. Single-guide RNA structure. In this work, the target-specific RNA sequence is comple-
mentary to the flavanone-3-hydroxylase (F3H) carrot (Daucus carota L.) gene (NCBI Acc. No. 
AF184270.1). 
Microbes have developed diverse CRISPR/Cas systems differing in the number and 
function of Cas proteins which often must form functional complexes capable of recog-
nizing, binding, and cleaving phage DNA. However, single proteins performing all these 
functions have been identified [11]. The best characterized, and now commonly used for 
genome engineering, is the Streptococcus pyogenes Cas9 (SpCas9, pCas9) protein. Cas9 is a 
class II, type II, nuclease consisting of seven domains: REC I, REC II, REC III, HNH, RuvC, 
PAM-interacting, and bridge helix (Figure 2) [16]. The REC I domain (blue colour) is re-
sponsible for a connection with gRNA. In turn, the REC III domain (cyan colour) is used 
to sense the formation of RNP complex. The PAM-interacting domain (red colour) recog-
nizes the PAM sequence at the target DNA. The arginine-rich bridge helix (pink colour) 
plays a key role in binding target DNA and modulates cleavage activity of the Cas9 pro-
tein [17]. Bot, HNH (green colour) and RuvC (yellow colour) domains are responsible for 
Figure 1. Single-guide RNA structure. In this work, the target-specific RNA sequence is complementary t the flavanone-3-
hydroxylase (F3H) carrot (Daucus carota L.) gene (NCBI Acc. No. AF184270.1).
Microbes have developed diverse CRISPR/Cas systems differing in the number and
function of Cas proteins which often must form functio al complexes capable of recog-
nizing, binding, and cleaving phage DNA. However, single proteins performing all these
functions have been identified [11]. The best characterized, and now commonly used for
genome engineering, is the S reptococcus pyoge es Cas9 (SpCas9, pCas9) protein. Cas9 is
a class II, type II, nuclea e c nsisting of seven dom ins: REC I, REC II, REC III, HNH,
R vC, PAM-interacting, and bridge helix (Figure 2) [16]. The REC I domain (blue colour)
is respons ble for a connection with gRNA. In turn, the REC III domain (cyan colour) is
used to se se the formation of RNP complex. The PAM-i teracting domain (red colour)
recognizes the PAM s quence at the a get DNA. The arginine-rich bridge helix (pink
colo r) plays a key ole in binding t et DNA and modulates cleavage activity of the Cas9
protein [17]. Bot, HNH (green colo r) and RuvC (yellow colour) domains are responsible
for cleavage; each of them cleaves a single DNA strand 3 nt up tream of PAM that leads to
a double-strand break [18,19]. The role of REC II domain (gray colour) has not been fully
elucidated, yet, but it seems not critical for DNA cleavage [16,20].
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Figure 2. The structure of Streptococcus pyogenes Cas9 protein, which contains seven domains: Rec I, Rec II, REC III, Bridge
Helix, RuvC, HNH, and PAM-interacting. Domains are presented in crystal (A), schematic (B), and map (C) form. Crystal
image was rendered from RCSB PDB ID: 4CMP [19], using PyMOL software (Schrödinger Inc., New York, NY, USA).
The development of efficient CRISPR/Cas systems for genome editing or for other
research purposes requires the selection of a proper Cas variant and designing correct
gRNA. The ability of both components to form active RNP complex must be verified exper-
imentally. Hence, a fast and non-destructive analytical method confirming RNP complex
formation would be valuable. Here, we present an electronic circular dichroism (ECD)
study on the Cas9 protein in its native form and bounded with gRNA. ECD spectroscopy
is based on a differential absorption of left- and righthanded circularly polarized light in
the UV-Vis range by chiral molecules. It is widely used to monitor structural changes of
organic compounds or important macromolecules in solution [21,22] as nucleic acids [23,24]
and proteins, especially to estimate the secondary structure of proteins including α-helix,
β-sheet, or random coil [25–27]. Proteins give strong ECD signals in the far-UV region,
dominated by the nπ* (~220 nm) and ππ* (~190 nm) transitions of amide groups, which are
influenced by the geometries of the polypeptide backbones and reflective of the different
types of secondary structures. In contrast to the other techniques like X-ray crystallography
and NMR, ECD does not require much time and specific condition of preparing a sam-
ple [28]. Thus, a good quality ECD spectrum can be obtained for a quite low concentration
of protein, in neutral water environment and with a short acquisition time (in 30 min
or less). Hence, ECD measurement, possibly supported by theoretical calculations, is a
powerful tool to examine the structure of proteins [28,29]. What is more, there are only a
few reports engaging ECD spectroscopy, in a very little extent, to analyse CRISPR/Cas
systems [30–33]. Two of them concern the Cas9 protein specifically [30,32]. So, we found
that ECD can be considered as a quick and effective method to identify the gRNA:Cas9
RNP complex. To confirm this approach is non-destructive to the protein and its complex
with RNA, we induced also in vitro DNA cleavage to show the biological activity of RNP
after ECD measurements.
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2. Results
2.1. Circular Dichroism of Cas9 Protein and gRNA
To determine secondary structure of Cas9 protein, ECD measurements were per-
formed. Recorded ECD and UV-Vis spectra are presented in Figure 3 (blue line). Proteins
give strong ECD signals in the range of 185–300 nm, which carry information about their
secondary structure. For Cas9, ECD profile reveals two negative and one positive pattern
located at 221, 209, and 196 nm, respectively. Intensities of negative bands are slightly
different, as indicated by the calculated ratio [θ]221/[θ]209 = 1.12. In addition, these bands
are much more intense than the positive ones. In turn, the maximum of UV-Vis absorption
for Cas9 protein is located at 191 nm (Figure 3).
Figure 3. ECD and UV-Vis spectra of Cas9 protein (blue line, C = 9.35 × 10−7 M) and gRNA (gray
line, C = 1.07 × 10−5 M).
The ECD spectrum registered for gRNA is also shown in Figure 3 (gray line). Going
from longer to shorter wavelengths, the spectral profile exhibits positive/negative/positive/
negative pattern of ECD bands situated at 266, 242, 222 and 209 nm, respectively. The
UV-Vis spectrum of gRNA reveals maximum at 257 nm and a shoulder at around 204 nm.
2.2. Circular Dichroism of the RNP Complex
To find an effective and quick method for identification of the gRNA:Cas9 complex,
ECD measurements were performed also for the RNP complex solution. Collected ECD
and UV-Vis spectra are presented in Figure 4. The RNP ECD profile (red line) shows the
positive/negative pattern of the bands located at 273 and 235 nm. The intensities of these
bands are approximately one order in magnitude lower than the one in the spectrum of
Cas9 protein (blue line). Moreover, the ECD spectrum of RNP complex differs significantly
from the ECD spectrum of unassociated gRNA (light gray line). Both spectra have similar
positive/negative pattern of two following bands going from longer to shorter wavelengths.
However, those ECD bands have different positions and are shifted in relation to each other.
The ECD spectrum of gRNA reveals also additional bands situated at 222 and 209 nm.
The UV-Vis spectrum of the gRNA:Cas9 complex shows tree maxima, observed at 258,
217 and 191 nm, two of which can be assigned to gRNA (258 nm) and protein (191 nm),
and the band at 217 nm cannot be assigned to any of the components.
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Figure 4. ECD and UV-Vis spectra of the Cas9:gRNA complex (red line and left scale; in the 1:1 molar
ratio with individual concentrations CCAS9 = 9.98 × 10−6 M and CgRNA = 1.07 × 10−5 M) in compar-
ison to the spectra of the Cas9 protein (light blue line and the 1st right scale, C = 9.35 × 10−7 M) and
gRNA (light gray line and the 2nd right scale C = 1.07 × 10−5 M). ECD: electronic circular dichroism.
2.3. Biological Activity of the Cas9 Protein and RNP Complex
The Cas9 biological activity after ECD measurements was verified by inducing DNA
cleavage in vitro and the sizes of the obtained ROX-labelled DNA fragments were deter-
mined using capillary electrophoresis. Fluorescent signals from untreated sample revealed
the presence of DNA, which size was exclusively 309 bp (Figure 5A). The same sample was
incubated with the RNP complex, which was not used for ECD measurements (control).
After incubation, fluorescent signals were obtained predominantly from DNA fragments
of 162 bp in length (Figure 5B). Weaker signals from shorter (150–161 bp) fragments were
also present while the 309 bp fragment signal was very weak. The presence of 162 bp or
shorter fragments indicated that almost all DNA was cleaved by the control RNP complex.
The ECD measurements of Cas9 protein were performed and then such protein was
used for RNP complex formation. Independently, a new RNP complex was prepared
by incubating unused gRNA and Cas9, and then such RNP complex was subjected to
ECD measurements. Both complex types, the RNP complex containing ECD-measured
Cas9 and ECD-measured RNP complex, were used for DNA cleavage in vitro to check
their biological activity. For both samples, electropherograms showed fluorescent signals
indicating the presence of short DNA fragments of the same size as in the control, i.e.,
predominantly 162 bp fragments (Figure 5C,D).
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Figure 5. Electropherograms of ROX-labelled DNA fragments detected by a capillary electrophoresis.
Untreated DNA of 309 bp in length (A), DNA incubated with the untreated RNP complex—control
(B), DNA incubated with the RNP complex containing ECD-measured Cas9 (C), DNA incubated
with the ECD-measured RNP complex (D). Stars—GeneScan™ 500 LIZ size marker.
3. Discussion
3.1. Cas9 and gRNA:Cas9 Complex Structures Revealed by ECD Spectroscopy
Based on ECD spectroscopy, a secondary structure of protein like α-helix, β-sheet
or random coil can be identified [27,28]. Excitation of a number of closely connected
chromophores (peptide bonds), being in a regular spatial disposition in protein, gives
rise to characteristic spectral features below 240 nm. The experimental ECD spectrum of
Cas9 protein (Figure 3, blue line) shows negative/positive pattern, like α-rich proteins,
with two negative bands of nearly the same intensity, observed at 221 and 209 nm, accom-
panied by the positive one at 196 nm. The origin of these ECD bands is assigned to the
nπ*, ππ*||(parallel to the helix axis) and ππ*⊥ (perpendicular to the helix axis) electronic
transitions of the peptide bond, respectively [27,34], where n is the nonbonding molecular
orbital, π is the HOMO level, while π* refers to the LUMO state [34]. In contrast to a typical
α-helix ECD spectrum [35], the positive Cas9 band is slightly red-shifted (192→196 nm)
and shows twice-lower intensity than negative ones, which in consequence shows an
impact of the remaining secondary structures in the protein. According to the crystallo-
graphic data, the SpCas9 molecule adopts a crescent shape with approximate dimensions
of 100 Å× 100 Å× 50 Å [19]. Its secondary structure is determined by α-helices with about
a twice-less content of stranded antiparallel β-sheets that, in turn, are the most prevailing
in the PAM-interacting and RuvC domains [36] (Figure 2A). Moreover, using an interactive
interface to the STRIDE program [37] presented in detail by Frishman and Argos [38], the
percentage content of individual secondary structure can be estimated based on knowledge
of the atomic coordinates of proteins. Thus, according to calculations based on the STRIDE
program, beyond the main contribution of α-helix (49.6%), the SpCas9 protein also contains:
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4% of 310-helix, 9.4% of β-sheet, 1.6% of β-bridge and 17% of β-turn classified as I, I′, II, II′,
VIa and VIb [39]. The remaining of 18.6% is a random coil structure. Hence, the decrease in
intensity, as well as the position of positive band at 196 nm in the Cas9 ECD spectrum may
be attributed to the presence of 310-helix, what was theoretically predicted by Manning and
Woody [40]. The 310-helix is a relatively common structural element in globular proteins
(3%), occurring often at the ends of α-helices [41,42]. The average conformational param-
eters of both helices are rather close to each other, but the 310-helix is gently tighter and
more elongated, as well as is characterized by the different C=O···H−N intermolecular
hydrogen bonding scheme [41,43]. Then, Toniolo et al. [44] reported the experimental ECD
spectrum of 310-helix, confirming the positive band of very weak intensity near 195 nm.
However, as opposed to the theoretical calculations, another negative strong maximum at
184 nm, not seen here (Figure 3, blue line), was also registered. The 310-helix seems to have
a positive signal around 190 nm of an uncertain magnitude [45]. Therefore, it cannot be
definitively determined whether the presence of the 310-helix in Cas9 protein contributed
to the intensity reduction of the positive Cotton effect, and a higher contribution of β-sheet
than one might expect cannot be ruled out.
Certainly, the β-sheet content has also an impact on the Cas9 ECD profile, what is
observed in the spectra of α/β-rich proteins like ribonuclease A (21% α, 33% β) or subtilisin
(30% α, 18% β) [45]. Signals of α-helix are stronger than β-sheet ones, so proteins with
comparable amount of both secondary structures generally show the qualitive spectral
features of the α-helix keeping the same negative/positive ECD profile. Although some dif-
ferences in the intensity or localization of ECD bands are present, especially as a decrease in
intensity of positive band around 195 nm in ribonuclease A spectrum [45]. Significant effect
on protein ECD pattern may have also β-turns [45,46], enabling reversal of the polypeptide
chain direction. These motifs constitute as the third most common secondary structural
elements occurring in proteins. For example, the type I reveals α-helix-like ECD spectrum,
while the type II shows a β-sheet-like one, what was confirmed experimentally [47]. The
Cas 9 has β-turn motifs in its structure, what may be manifested in reduced intensity of
the positive band at 196 nm, as well as in a gentle difference in intensity between negative
ECD bands ([θ]221/[θ]209 = 1.12).
In contrast to ECD spectroscopy, UV-Vis spectra of different proteins secondary confor-
mations do not reveal specific features, besides slight shift of the main electronic transition.
The Cas9 UV-Vis spectrum (Figure 3, blue line) has only one maximum at 191 nm that is
typical for pure α-helix structure and comes from the ππ* excitation in the amide group [48].
Like proteins, the absorption spectra of nucleic acids are dominated by ππ* electronic
transitions, which are all polarized in the plane of the bases. Moreover, both wavelength
maxima and transition intensities vary depending on the base sequence and structure
adopted [48]. Nonbonding electrons of the amide-like oxygens can be also excited to
π* orbitals; however, nπ* transitions are characterized by low intensity and are usually
buried by the intense ππ* ones [49]. Here, we observe maximum of UV-Vis gRNA band
at 257 nm (Figure 3, gray line), which can be assigned to ππ* excitation and corresponds
to the literature data recorded for various polynucleotides [48]. In turn, the experimental
ECD spectrum of gRNA (Figure 3, gray line) shows positive/negative/positive/negative
pattern with bands observed at 266, 242, 222 and 209 nm, respectively, what is typical for
the A-type helix geometry assigned to RNA duplexes [50,51]. Thereby, it confirms that
gRNA has the repeat and anti-repeat regions adopting the A-form-like conformation [52].
In general, RNA is formed by canonical double-helical fragments, along with non-canonical
secondary structure motifs like internal loops, hairpins, bulges, and the most widespread
ones: single mismatches [53]. All these motifs play relevant functions in providing binding
sites for proteins, small molecules, or nucleic acids, and have impact in folding the correct
tertiary and quaternary structures. Theoretical calculation shows that ECD signal of
polynucleotides mainly origins from the exciton coupling interaction between bases stacked
in asymmetric structure of higher ordering like helices, than from the base-sugar interaction
in monomeric nucleotides, as well as it arises for the most part from the ππ* transitions,
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rather than nπ* ones [54]. Thus, perturbation of a nucleic acid ECD profile, that appears
due to binding of a protein, generally reflects changes in short-range base–base interactions,
providing confirmation for transitions between secondary structures (A↔B, B↔Z) or
alternations in base pairing, base stacking, or bending of a DNA or RNA duplex [55].
Despite a lot of ECD studies describing protein—nucleic acids interactions [55,56],
here we present for the first time the experimental ECD spectrum of gRNA:Cas9 RNP com-
plex (Figure 4, red line). This unique RNP hybrid reveals positive/negative ECD pattern
with bands located at 273 and 235 nm, which differs significantly from individual spectral
profiles of each macromolecule. The Cas9 upon gRNA binding changes dramatically its
structure through wide intermolecular rearrangements. According to the literature, one
of the most prominent changes takes place in the REC III domain, which moves ∼65 Å
toward the HNH domain due to gRNA connection [20], what is definitely reflected by the
characteristic ECD spectral profile of RNP hybrid in comparison to the ECD spectrum of
a free protein (Figure 4, light blue line). Moreover, using the STRIDE server [37] and the
crystallographic data PDB ID 4ZT0 [57], the percentage content of individual secondary
structure in active RNP complex can be provided: 41.5% of α-helix, 4.5% of 310-helix, 10.7%
of β-sheet, 2% of β-bridge, 22.4% of β-turn and 18.8% of random coil structure. Based on
presented data, it can be concluded that the Cas9 changes its secondary structure elements
upon gRNA binding, mainly through loss of α-helicity (49.6→41.5%), and slight increase in
the content of β-turns (17→22.4%). However, it is hard to determine those changes from the
RNP ECD profile, which has no representative spectral features for still-prevalent α-helix
structure. A major change in α-helical content undergoes also among a DNA binding
proteins like transcription factors, which have been mostly studied among proteins by
ECD below 250 nm [55]. Unlike the gRNA:Cas9 complex, transcription factors exhibit an
enhancement of α-helix structure in the bound state around 10–15%. However, in some
cases like recombination activation gene 1 protein (the RAG1) [58] and human translin
protein [59], a strong decrease in the protein α-helicity after nucleic acids complexation was
confirmed. On the other hand, the ECD spectrum of RNP complex is strongly red-shifted
and do not reveal any characteristic bands below 220 nm, which can be assigned to any
of the protein secondary structures. In addition, its ECD signals do not coincide with the
gRNA spectrum indicating that the polynucleotide chain adopted also different geometry
due to connection with the Cas9 protein. What is interesting, there are some similari-
ties in ECD patterns between the gRNA:Cas9 complex and chromatin [60], especially in
the range 240–300 nm that is practically the same in both cases. The ECD spectrum of
the complex between EsColi ribonuclease and RNA also bears some resemblance to the
RNP [61]. However, the RNP ECD profile is very individual and it is hard to compare with
literature results obtained for other protein–nucleic acid hybrids. The UV-Vis spectrum
of gRNA:Cas9 (Figure 4, red line) differs somehow from those of Cas9 and gRNA, but it
includes absorption bands characteristic of each macromolecular component and does not
allow to monitor changes in secondary structure geometry.
3.2. Cas9 Binds gRNA and Retains Cleavage Activity after ECD Measurements
We have previously demonstrated that carrot genome can be edited by delivering
S. pyogenes Cas9 and gRNA expression vectors to living cells which led to the RNP com-
plex formation in vivo [62]. The gRNA was designed to target the 20 nt sequence of the
flavanone-3-hydroxylase (F3H) gene located upstream the GGG PAM sequence. Sequenc-
ing analysis revealed that the target DNA was cleaved usually 3 bp upstream of PAM,
although small nucleotide deletions in close proximity were also identified in some samples.
In this work, we have verified that the measurements using ECD spectroscopy do
not affect Cas9 biological activity by performing in vitro DNA cleavage experiments.
Verification of RNP complex activity using in vitro cleavage has been reported earlier
and such approach has several advantageous over experiments with living cells: it is
fast, performed in controlled conditions, and the results are not affected by complex cell
processes [63]. For that purpose, we assembled the above said gRNA molecules and
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obtained their complexes with SpCas9 to carry out in vitro cleavage of DNA utilizing
a laboratory-amplified fragment of the F3H carrot gene as the target. The used gRNA
was designed to guide Cas9 protein to the 309 bp DNA and to enable DNA cleavage
at the selected target site to two, 162 bp and 147 bp, fragments. A fluorescent capillary
electrophoresis was employed to confirm cleavage due to its high accuracy [64]. As the
used DNA was ROX-labelled at only one end, the fluorescent signals registered during
a capillary electrophoresis could originate from the unmodified DNA molecules and 162
bp cleaved products. The in vitro DNA cleavage and detection of predominantly 162 bp
products confirmed the activity of control RNP complex, as expected.
Using the same approach, two other RNP complexes were also checked for their
biological activity. In contrast to the control, either the whole RNP complex was subjected
to ECD measurement before in vitro DNA cleavage experiments or only the Cas9 protein
was measured prior to the RNP complex formation, and then this complex was measured
using ECD. In all samples, the expected 162 bp cleaved fragments were identified. No
essential difference in the activity of RNP complexes was found nor their activity differed
from the control. Hence, in vitro DNA cleavage confirmed that: (1) gRNA was properly
designed and synthesized, (2) Cas9 protein was able to form complex with gRNA, (3)
gRNA properly directed Cas9 to the target DNA site, and (4) Cas9 had cleavage activity.
Moreover, the same conclusions apply to the ECD-measured Cas9 protein used for RNP
complex formation. The ECD measurements did not restrict Cas9 protein ability to interact
with gRNA and DNA nor its enzymatic activity. Furthermore, ECD measurements of
the already formed RNP complex also did not affect these properties. Hence, it can be
concluded that after ECD measurements Cas9 retains its structure capable to form an active
complex with gRNA to efficiently cleave DNA.
The obtained results provide new opportunities for analytical validation of correct
gRNA designing. The ECD spectroscopy can be used to confirm the presence of RNP
complexes in the sample without adverse effects on their biological activity. This is in
particular valuable in case of unsuccessful DNA cleavage performed in vivo or in vitro.
As indicated above, several requisites must be fulfilled for efficient DNA cleavage by
RNP complex [13,16,20]. Therefore, the lack of cleaved products may be due, inter alia, to
aberrant interaction of gRNA with the Cas protein. The detection of such events would be
valuable in research aiming in verification of gRNA differing in their structure. In particular,
the Cas activity depends on the gRNA length and tracrRNA fragment structure [65,66].
Also new Cas protein variants have been reported and they differ in structure which, in turn,
determines the structure of interacting gRNA [3,13]. Hence, complementing experimental
and bioinformatic approaches to studying RNP complexes [67], ECD spectroscopy can help
reveal Cas–gRNA compatibility in a fast and simple fashion.
4. Materials and Methods
4.1. Cas9 Protein
Streptococcus pyogenes Cas9 (EnGenTM Spy Cas9 NLS) protein was purchased from
New England Biolabs Inc. (Ipswich, MA, USA) as a buffer solution (300 mM NaCl;
10 mM Tris-HCl; 0.1 mM EDTA; 1 mM DTT; 50% glycerol) with a protein concentration of
3.22 mg/mL (100 µL; 2000 pmol).
4.2. gRNA Design and Transcription
The 20 nt target-specific RNA sequence of single-guide RNA (Figure 1) was designed
to target the second exon in the flavanone-3-hydroxylase (F3H) carrot (Daucus carota L.)
gene (NCBI Acc. No. AF184270.1) at 632–651 position (GAAGTTTTGTCAGAGGCCAT)
using the CasOT software [68]. The complementary DNA oligonuclotide was synthesized
commercially (Genomed, Warsaw, Poland). This fragment was assembled with oligonu-
cleotides of the tracrRNA part of the gRNA using the GeneArt™ Precision gRNA Synthesis
Kit (Invitrogen, Carlsbad, CA, USA), and the final product was transcribed to the gRNA
Int. J. Mol. Sci. 2021, 22, 2937 10 of 14
molecules according to the kit manufacturer’s recommendations. The correct assembly and
nucleotide sequence of gRNA was confirmed by sequencing (Genomed, Warsaw, Poland).
4.3. Formation of the gRNA:Cas9 RNP Complex
The synthesized gRNA was mixed with Cas9 in 1:1 molar ratio and incubated at 37 ◦C
for 20 min in order to form the RNP complex. In detail, 4.24 µL of the 7.58 mg/mL gRNA
solution was added to 50 µL of the 3.22 mg/mL Cas9 solution. The obtained mixture was
vortexed and then incubated. The RNP complex was used either for ECD measurement or
for in vitro DNA cleavage.
4.4. UV-Vis/ECD Measurements
Samples of Cas9 protein, gRNA and RNP complex were measured by means of
UV–Vis/ECD spectroscopy using JASCO J-815 spectrometer (JASCO Corporation, Tokyo,
Japan). To avoid supersaturation of the detector, all samples were diluted with very clear
nuclease-free water. The concentration of the individual solutions was: 9.35 × 10−7 M
for the Cas9 protein, 1.07 × 10−5 M for the gRNA in both single and RNP form, as well
as 9.98 × 10−6 M for the Cas9 nuclease in RNP complex. All UV–Vis/ECD spectra were
recorded with the use of 0.1 cm path length quartz cuvette, as well as with the following
settings: 185–350 nm spectral range, 100 nm/min scanning speed, 1 nm bandwidth, 0.2 nm
step size, 0.5 s response time and 10 scans of accumulation. Finally, baseline and solvent
corrections were done with the JASCO software (JASCO Corporation, Tokyo, Japan).
4.5. DNA Amplification
Two HPLC purified primers (F: 5′-GCAAGATTGGCGAGAGATAG-3′ and R: 5′-
AGCAAGAGCGTAATTGTGCC-3′) designed for the amplification of 309 bp DNA fragment
of the second exon in the F3H carrot gene (NCBI Acc. No. AF184270.1) during polymerase
chain reaction (PCR) were ordered from Genomed company (Warsaw, Poland). The F
primer was labelled with the ROX fluorescent dye at its 5′ end. The PCR reaction mixture
set up in 20 µL volume contained 0.1 µM of each primer and a commercial 2× buffer
composed of Taq polymerase and dNTPs (PCR Mix Plus, A&A Biotechnology, Gdynia,
Poland). The reaction was carried out in the Eppendorf Mastercycler thermocycler (Eppen-
dorf, Hamburg, Germany) with the following conditions: the initial denaturation at 94 ◦C
for 4 min, 35 cycles of 45 s at 94 ◦C, 30 s at 60 ◦C, and 60 s at 72 ◦C, and the final extension
at 72 ◦C for 5 min.
4.6. In Vitro DNA Cleavage
The RNP complex, in the amount of 9 µmol Cas9 and 9 µmol gRNA, was mixed
with 0.9 µmol of the PCR amplified 309 bp DNA fragments, which were earlier purified
on a column (Wizard® SV Gel and PCR Clean-Up, Promega, Madison, WI, USA). The
final reaction mixture contained 10xNEBuffer 3.1 (100 mM NaCl, 50 mM Tris-HCl, 10 mM
MgCl2, 100 µg/mL BSA) adjusted to 30 µL volume in RNase free water. DNA cleavage
was performed at 37 ◦C for 15 min followed by 10 min incubation at RT, after the addition
of 1 µL of Proteinase K (Sigma-Aldrich, St. Louis, MO, USA). The DNA fragments were
separated using a capillary electrophoresis (3730XL DNA Analyzer, Applied Biosystems,
Foster City, CA, USA) combined with the detection of fluorescent dyes. DNA fragment
sizes were determined using the GeneScan™ 500 LIZ size marker (Thermo Fisher Scientific,
Waltham, MA, USA) and visualized using the PeakScanner v.2.0 software (Thermo Fisher
Sci., Waltham, MA, USA).
5. Conclusions
In this work, characteristic spectra of the Cas9 protein, gRNA, and their complex were
registered using ECD spectroscopy. In particular, the RNP complex showed a distinctive
spectral pattern resulting from some structural rearrangements in the Cas9 protein. The
formation of RNP complex as well as its activity is determined by the structure of Cas
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protein and interacting gRNA molecule. Hence, we show that ECD spectroscopy can be
used for verification of the Cas9 ability to bind specific gRNA and for identification of
the successfully formed RNP complex. Moreover, the activity of the RNP complex was
further confirmed by conducting the in vitro DNA cleavage. The results show that either
Cas9 protein or RNP complex retain their biological activities after the ECD measurements,
and they are able to bind and cleave the target DNA. The experiments have shown the
potential of the ECD in structural studies of various Cas proteins and their interactions with
specific gRNAs, in an undoubtedly non-destructive manner. To facilitate the research and
use of continuously and fast evolving CRISPR/Cas-based systems in biological sciences,
reliable and simple techniques allowing characterization of the CRISPR/Cas individual
components are needed, and ECD can be considered as such.
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